Natural Killer Cell Therapy: A Look Inside a ‘Living Drug in a Bottle’

July 9, 2019
The ability to harness the human immune system and use it to fight cancer remains a significant area of focused research and is likely to remain so…
In the JournalsPerspective

Despite ‘incremental’ progress, long-term survival rates ‘have not budged’ in glioblastoma

July 8, 2019
Although median and short-term OS rates have improved for glioblastoma, still only a small proportion of patients achieve 5-year survival, according…

Therapeutic vaccine could improve checkpoint blockade efficacy for patients with cancer

July 3, 2019
Researchers at Icahn School of Medicine at Mount Sinai have developed a novel vaccine that uses immune stimulants to inhibit cancer cell growth among…
Meeting NewsVideo

VIDEO: Eribulin plus pembrolizumab shows no clinical benefit in breast cancer subtype

July 2, 2019
CHICAGO — The addition of pembrolizumab to eribulin demonstrated no significant improvements in terms of PFS, OS or objective response rate…
Meeting News

Guest Commentary: Frontline pembrolizumab noninferior to chemotherapy in certain GI cancers

June 29, 2019
In this Guest Commentary, Diana L. Hanna, MD, assistant professor of clinical medicine at the University of Southern
Meeting News

Guest Commentary: ‘Intriguing’ ASCO data highlights new excitement in colorectal cancer

June 27, 2019
In this Guest Commentary, HemOnc Today Next Gen Innovator Van Morris, MD, medical oncologist in the department of gastrointestinal medical
Advanced Practice

Understanding affected anatomy, physiology essential to management of taste disorders

HemOnc Today, June 25, 2019
David L. Jennings II, MSN, RN, AGPCNP-BC
Editor’s note:HemOnc Today’s regular columns for advanced practice providers (APPs) tackle common issues APPs face, discuss day-to-day
Cover Story

Despite promising new regimens, search for cure is ‘highest priority’ in advanced renal cell carcinoma

HemOnc Today, June 25, 2019
With approximately 73,820 diagnoses and 14,770 deaths expected this year in the U.S., renal cell carcinoma remains a cancer in need of new treatment…
Molecular Oncology

Therapeutic armamentarium in urothelial carcinoma grows with understanding of tumor biology

HemOnc Today, June 10, 2019
Petros Grivas, MD, PhD
Bladder cancer is one of the most common forms of cancer in United States, with an estimated 81,190 new cases and 17,240 deaths in 2018. Urothelial…

Will new therapies for sickle cell disease lead to a change or reduction in use of hydroxyurea for the management of pain?

HemOnc Today, June 10, 2019
POINT Over the last 20 years, strong and consistent evidence has demonstrated when children and adults with sickle cell disease are adherent to…